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1ABSTRACT1
Background2
Pyoderma gangrenosum is a rare inflammatory skin condition. The STOPGAP studies3
compared treatments for pyoderma gangrenosum using a primary outcome of healing speed at4
6 weeks.5
Objective6
Using data from both studies we assessed the predictive value of three early predictors for7
healing at 6 months - speed of healing, Investigator Global Assessment and resolution of8
inflammation, recorded at 2 and 6 weeks.9
Methods10
Logistic regression models were applied and the effectiveness of the three measures was11
assessed through estimating the positive (PPV) and negative predictive values (NPV) and the12
area under the receiver operating characteristic curve (AUC).13
Results14
The PPV and NPV at 6 weeks were 63.5% (95% CI:52.4%, 73.7%) and 74.6% (95%15
CI:62.5%, 84.5%) respectively for speed of healing; 80% (95% CI:68.7%, 88.6%) and 74.2%16
(95% CI:64.1%, 82.7%) for IGA; and 72.1% (95% CI:59.9%, 82.3%) and 68.1% (95%17
CI:57.7%, 77.3%) for resolution of inflammation. Investigator Global Assessment had the18
best combined PPV, NPV and AUC at 2 and 6 weeks.19
Limitations20
We were limited by data available from the STOP GAP trial and cohort study.21
Conclusion22
Speed of healing, Investigator Global Assessment and resolution of inflammation were all23
shown to be good predictors of eventual healing.24
2KEY WORDS25
pyoderma gangrenosum; speed of healing; lesion improvement; resolution of inflammation;26
predictors; clinical trials; clinical practice27
28
CAPSULE SUMMARY29
 Speed of healing has been shown to be a good predictor of eventual healing for leg ulcers.30
 Here, speed of healing, Investigator Global Assessment and resolution of inflammation are31
all good predictors of eventual healing for pyoderma gangrenosum.32
 This finding is helpful for informing future trial design and clinical decision-making.33
34
35
3ABBREVIATIONS36
STOP GAP - Study of Treatments fOr Pyoderma GAngrenosum Patients37
RCT – randomised controlled trial38
PPV – positive predictive value39
NPV - negative predictive values40
AUC - area under the receiver operating characteristic curve41
42
43
4INTRODUCTION44
Pyoderma gangrenosum is a rare inflammatory skin condition that causes tissue to become45
necrotic, leaving deep ulcerative lesions. These ulcers can be painful, rapidly spread, and may46
take many months to heal.1 There is a paucity of evidence for pyoderma gangrenosum47
treatments.2 Most evidence is based on observational studies and only two randomised48
controlled trials (RCTs) have been conducted to date.1, 3 One of the challenges of conducting49
research into rare skin conditions such as pyoderma gangrenous, is the lack of validated50
outcome measures for assessing treatment response.51
The primary outcome for two recently completed studies (STOP GAP randomised controlled52
trial3 and STOP GAP prospective cohort study4 was speed of healing over the first 6 weeks53
of treatment. Initial treatment response was used as a surrogate measure for time to healing;54
which is more clinically-relevant in that it influences patient satisfaction, cumulative drug55
exposure and drug safety.56
Speed of healing, if valid, could become a useful surrogates for eventual healing and could be57
used to guide early treatment decisions in clinical practice.58
Although speed of healing has been shown to be a good predictor of healing in patients with59
leg ulcers caused by venous disease 5, 6, it is unclear whether the same applies to patients with60
an inflammatory condition such as pyoderma gangrenosum.61
Using data from the STOP GAP trial and cohort study, we investigated whether speed of62
healing in the first 6 weeks of treatment was a good indicator of subsequent healing in63
patients with pyoderma gangrenosum, or whether other measures, such as Investigator Global64
Assessment for lesion improvement, or resolution of inflammation, were more useful65
66
5METHODS67
This work involved secondary data from previous studies and as such did not require specific68
approval from an Institutional Review Board.69
Study conduct70
Ethics and regulatory approvals were obtained for the STOP GAP trial and cohort studies71
(ethics: 09/H0903/5, Medicines and Healthcare Products Regulatory Agency:72
19162/0213/001); all participants gave written informed consent. Oversight of the study was73
performed by independent Trial Steering Committee and Data Monitoring Committee.74
Specific ethical approval for this study was not required.75
Summary of the STOP GAP trial and STOP GAP cohort study76
Both the RCT and the cohort study included adults with a clinical diagnosis of pyoderma77
gangrenosum (as confirmed by a dermatologist, with biopsy as required), and followed78
participants for a maximum of 6-months. For the STOP GAP trial, participants were79
randomised to receive either ciclosporin or prednisolone, and in the cohort study, participants80
received topical therapy according to local practice (49 / 74% received clobetasol propionate81
0.05%).82
For participants with multiple lesions, a target lesion was chosen for study. This was defined83
as being the largest lesion on a single plane (i.e. not around the curvature of a limb). Lesions84
were measured by physical measurements taken by the clinician. Grade for lesion85
improvement was also measured by the clinician using an Investigator Global Assessment86
(IGA) and resolution of inflammation was measured using the scale reported by Foss 7.87
Details of each of these scales are given in Supplementary File 1.88
For patients participating in the RCT, lesion size, grade for lesion improvement (IGA) and89
resolution of inflammation were also assessed by an independent assessor using digital90
6images. For lesion size the measurements were taken from the digital images using VEV91
computerised planimetry. An example of measurements being taken from a digital image is92
shown in Supplementary File 2. These measurements were used in the analyses of the primary93
and secondary outcomes in the RCT. Where digital images were not available or were of poor94
quality, the physical measurements recorded by the clinician were used instead. These95
physical measurements approximated lesion area through the formula: length x width x 0.78596
Outcomes were captured at baseline, 2 weeks, 6 weeks and when the ulcer had healed (up to a97
maximum of 6 months). Lesions were considered to have healed when sterile dressings were98
no longer required as reported by patients. If this information was missing, then healing as99
confirmed by a clinician at the next clinic visit was used instead. Further details of the100
STOPGAP trial and cohort study are described elsewhere.3, 4101
Patient populations102
The sample size for this study was based on available data. We analysed data from 112103
patients who participated in the STOP GAP trial4 and 67 patients from the cohort study.4104
Methods for assessing predictors of healing105
We assessed three possible early indicators for healing or non-healing by 6 months. The first,106
speed of healing at 2 and 6 weeks, was estimated as follows:107
108
Speed of healing=
Lesion area at 2 or 6 weeks-Lesion area at baseline
Time between visits (~2 or 6 weeks)
109
Investigator Global Assessment as reported by the clinician at 2 weeks and 6 weeks, as well110
as resolution of inflammation using the scale reported by Foss 7 at 2 weeks and 6 weeks were111
7also considered as possible early indicators for healing or non-healing by 6 months.112
Investigator Global Assessment was treated as a categorical variable (1 "Completely/almost113
clear", 2 "Marked improvement", 3 "Moderate improvement", 4 "Slight improvement", 5 "No114
change/worse"). Resolution of inflammation was treated as a binary variable (successful/not115
successful), with success defined as erythema and border elevation reduced to “none”.116
Healing status by 6 months was treated as a binary outcome; healed or not healed. Logistic117
regression models were used to test the effectiveness of each of the three measures as118
indicators for healing or non-healing by 6 months. The models were adjusted for age, gender,119
baseline lesion area, underlying systemic disease and lesion location.120
A logistic regression model was fitted in order to estimate the positive (PPV) and negative121
predictive values (NPV) along with the area under the receiver operating characteristic curve122
(AUC). The cut-off point for predicted probabilities was set at 0.5. An AUC value of 0.5123
demonstrates that the measures are non-predictive of healing or non-healing and a value of 1124
is be considered a perfect prediction (i.e. the measures discriminate perfectly between those125
who heal and those who don’t heal).8126
In terms of lesion area, for the purposes of this study, the physical measurements recorded by127
the clinician were used throughout. However, a sensitivity analysis was carried out just on the128
RCT data to establish whether the method of measurement (i.e. physical measurements or129
digital images) had an impact on the results.130
Statistical analyses were conducted using Stata v13 (Stata Corporation, TX, U.S.A).131
132
8RESULTS133
Participant characteristics and missing data134
A total of 179 patients were available for analysis - 112 patients who participated in the STOP135
GAP trial4 and 67 patients from the cohort study.4 The baseline characteristics of the 179136
patients are given in Table 1. One patient was missing a baseline lesion measurement and so137
was excluded from all analyses. At the 2 week visit, 18 patients were missing all three138
measurements for lesion size, Investigator Global Assessment and resolution of inflammation139
and so were excluded from all 2 week analyses. At the 6 week visit, 15 patients were missing140
all three measurements and so were excluded from all 6 week analyses. One patient was141
missing a measurement for resolution of inflammation and so was excluded solely from the 6142
week analysis for resolution of inflammation. Ten patients were missing lesion size at 6143
weeks and so were excluded solely from the analysis for speed of healing.144
Assessment of predictors of healing145
The PPV, NPV and AUC were calculated for the three different measures of early treatment146
response (Table 2). Figure 1 shows the receiver operating characteristic (ROC) curves at 2147
and 6 weeks for each of the three measures that were considered as predictors for healing or148
non-healing at 6 months.149
All three measures demonstrated an AUC greater than 0.7 at both 2 and 6 weeks. Investigator150
Global Assessment for grade of lesion improvement had the best combined PPV, NPV and151
AUC at 2 weeks and at 6 weeks.152
Physical measurements vs. digital images for speed of healing153
Of the 112 patients (104 after excluded missing data) who participated in the RCT, 86154
(82.7%) had their lesion size measurements based on digital images in addition to physical155
measurements. A sensitivity analysis was carried out to assess whether there were any156
9differences in terms of predictive value between speed of healing estimated using 100%157
physical measurements and speed of healing estimated using 82.7% digital images and 17.3%158
physical measurements. Table 3 gives the PPV, NPV and AUC for each of these as a159
predictor of healing at 6 months. In terms of predicting healing at 6 months, there were no160
significant differences between the digital images and physical measurements for speed of161
healing (Table 3).162
163
10
DISCUSSION164
Main findings165
Speed of healing, Investigator Global Assessment and resolution of inflammation were all166
shown to be good predictors of eventual healing. The Investigator Global Assessment was167
marginally the best of the three measures. In terms of the timing of assessments, the 6-week168
measurements were better predictors of eventual healing than assessments at 2 weeks, and169
would be the most advisable time-point to use in future trials. However, the 2-week170
measurements were reasonably predictive and could still be useful for clinical practice.171
Speed of healing estimated through physical measurements or digital images yielded no172
differences in terms of predicting eventual healing. This indicates that the digital images may173
be just as good as other clinical indicators. As such, if a blinded outcome is needed in future174
trials of pyoderma gangrenosum then digital images could be considered for this.175
These findings support the choice of primary outcome in the STOP GAP trial (speed of176
healing at 6 weeks, assessed by blinded assessors using digital images), and suggest that177
important clinical differences were not missed as a result of this focus on early treatment178
response.179
In addition, the Investigator Global Assessment and the resolution of inflammation scale were180
both shown to be good early predictors of healing . Both of these are relatively simple tools to181
use that could prove useful in clinical practice when making decisions on whether to stop,182
switch or alter doses of treatment.183
Relevance to other studies184
11
Several other studies have investigated early predictors of wound healing in venous and185
diabetic foot and leg ulcers. These studies reported early response at week 4 to be a good186
predictor of healing at 12 to 24 weeks5, 9, 10.187
Strengths and limitations188
This study is the first to assess the utility of early predictors of healing in patients with189
pyoderma gangrenosum and represents efficient re-use of data to inform clinical practice and190
trial design. Limitations of this study include the difficulty of defining the reference standard191
for eventual healing. Lesions were considered to have healed when sterile dressings were no192
longer required, which is a patient-orientated definition of healing. An alternative definition193
could have been complete healing of the lesion, but this would have required more frequent194
clinic assessments than were possible in the clinical trial. We were also limited by the data195
available from the STOP GAP trial and cohort study in that measurements were only taken at196
2 and 6 weeks after start of treatment. It is possible that other time points could have been197
equally good predictors of eventual healing.198
Conclusion199
Early treatment response appears to be a good indicator of eventual healing, regardless of how200
it is measured. This finding is helpful for informing future clinical trial design and clinical201
decision-making.202
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Figure 1: Pyoderma gangrenosum. Receiver operating characteristic (ROC) curves at 2241
weeks (a) and 6 weeks (b) for each of the three measures considered as predictors of healing242
or non-healing at 6 months.243
* Adjusted for age, gender, baseline lesion size, underlying systemic disease and lesion244
location.245
246
247
248
Characteristics N=179
Age 55.54 (16.66)
Female 118 (65.92%)
Location of target lesion:
Upper limbs
Lower limbs
Not limb
10 (5.59%)
115 (64.25%)
54 (30.17%)
Underlying systemic disease 59 (32.96%)
Baseline lesion area 7.64 (2.81 to 18.84)*
Table 1: Baseline characteristics of patients in the STOP GAP trial and the observational
study. Values are number (%), mean (standard deviation) or median (interquartile range).
*Based on 178 patients.
Time
Point
No.
patients
in
analysis
Positive
Predictive
Value
Negative
Predictive
Value
Area under ROC
curve (AUC)
Speed of
healing
2 weeks 159
68.3%
(55.3% to
79.4%)
67.7%
(57.4% to
76.9%)
0.7269
(0.6491 to
0.8046)
6 weeks 152
63.5%
(52.4% to
73.7%)
74.6%
(62.5% to
84.5%)
0.8073
(0.7404 to
0.8742)
Investigator
Global
Assessment
2 weeks 159
73.2%
(59.7% to
84.2%)
68.0%
(58.0% to
76.8%)
0.7808
(0.7098 to
0.8517)
6 weeks 163
80.0%
(68.7% to
88.6%)
74.2%
(64.1% to
82.7%)
0.8661
(0.8131 to
0.9192)
Resolution
of
inflammatio
n
2 weeks 159
66.1%
(53.0% to
77.7%)
66.0%
(55.7% to
75.3%)
0.7224
(0.6443 to
0.8006)
6 weeks 162
72.1%
(59.9% to
82.3%)
68.1%
(57.7% to
77.3%)
0.7728
(0.7015 to
0.8440)
Table 2: Predictive values and area under the receiver operating characteristic curve (AUC)
(95% confidence intervals) at 2 weeks and 6 weeks for the three measures considered as
predictors of healing or non-healing at 6 months.
* Adjusted for age, gender, baseline lesion size, underlying systemic disease and lesion
location.
Table 3: Sensitivity analysis to compare results at 6 weeks using physical measurements
alone, or a mixture of physical measurements and digital images. Analyses only carried out
on RCT data (n=104).
* Adjusted for age, gender, baseline lesion size, underlying systemic disease and lesion
location.
Method of
measurement
Positive
Predictive Value
Negative
Predictive Value
Area under ROC
curve (AUC)
Speed of
healing at 6
weeks
Physical
measurements only
69.0%
(55.5% to 80.5%)
80.4%
(66.1% to 90.6%)
0.8434
(0.7701 to 0.9168)
Mixture of physical
measurements
(17.3%) & digital
images (82.7%)
72.9%
(59.7% to 83.6%)
86.7%
(73.2% to 94.9%)
0.8623
(0.7936 to 0.9311)
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Grade for lesion improvement was measured by the clinician using the Investigator 
Global Assessment 
 
 
Resolution of inflammation was measured using the scale reported by Foss1 
 
INFLAMMATION ASSESSMENT OF THE TARGET LESION 
Please tick one box only for each section 
Erythema 
None  No erythema □(0) 
Slight  Mild pink colour □(1) 
Moderate  Moderate pink colour □(2) 
Severe  Reddish colour □(3) 
Very severe  Dark red or violaceous □(4) 
Border elevation 
None  Border is flat with ulcer and surrounding skin, no 
elevation □(0) 
Slight  Slight elevation of border above ulceration and 
surrounding skin □(1) 
Moderate  Noticeable elevation of border above ulceration and 
surrounding skin □(2) 
Severe  Significant elevation of border above ulceration and 
surrounding skin □(3) 
Very severe  Border rolled high above ulceration and surrounding 
skin □(4) 
 
INVESTIGATOR GLOBAL ASSESSMENT OF EFFICACY 
Grade Tick below 
0 Completely clear: except for possible residual hyperpigmentation □(0) 
1 Almost clear: very significant clearance (about 90%); however, patchy 
remnants of dusky erythema and/or very small ulceration 
□(1) 
2 Marked improvement: significant improvement (about 75%); however, 
a small amount of disease remaining (i.e remaining ulcers, although 
have decreased in size, minimal erythema and/or barely perceptible 
border elevation) 
□(2) 
3 Moderate improvement: intermediate between slight and marked; 
representing about 50% improvement 
□(3) 
4 Slight improvement: some improvement (about 25%); however, 
significant disease remaining (i.e remaining ulcers with only minor 
decrease in size, erythema or border elevation) 
□(4) 
5 No change from baseline □(5) 
6 Worse □(6) 

